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IMPORTANCE Patients with atrial fibrillation (AF) are at a proportionally higher risk of stroke
based on accumulation of well-defined risk factors.
OBJECTIVE To examine the extent to which prescription of an oral anticoagulant (OAC) in US
cardiology practices increases as the number of stroke risk factors increases.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional registry study of outpatients with AF
enrolled in the American College of Cardiology National Cardiovascular Data Registry’s
PINNACLE (Practice Innovation and Clinical Excellence) Registry between January 1, 2008,
and December 30, 2012. As a measure of stroke risk, we calculated the CHADS2 score and the
CHA2DS2-VASc score for all patients. Using multinomial logistic regressionmodels adjusted
for patient, physician, and practice characteristics, we examined the association between
increased stroke risk score and prescription of an OAC.
MAIN OUTCOMES ANDMEASURES The primary outcomewas prescription of an OACwith
warfarin sodium or a non–vitamin K antagonist OAC.
RESULTS The study cohort comprised 429 417 outpatients with AF. Their mean (SD) age was
71.3 (12.9) years, and 55.8%weremale. Prescribed treatment consisted of an OAC (192 600
[44.9%]), aspirin only (111 134 [25.9%]), aspirin plus a thienopyridine (23 454 [5.5%]), or no
antithrombotic therapy (102 229 [23.8%]). Each 1-point increase in risk score was associated
with increased odds of OAC prescription compared with aspirin-only prescription using the
CHADS2 score (adjusted odds ratio, 1.158; 95% CI, 1.144-1.172; P < .001) and the
CHA2DS2-VASc score (adjusted odds ratio, 1.163; 95% CI, 1.157-1.169; P < .001). Overall, OAC
prescription prevalence did not exceed 50% even in higher-risk patients with a CHADS2 score
exceeding 3 or a CHA2DS2-VASc score exceeding 4.
CONCLUSIONS AND RELEVANCE In a large quality improvement registry of outpatients with
AF, prescription of OAC therapy increased with a higher CHADS2 score and CHA2DS2-VASc
score. However, a plateau of OAC prescription was observed, with less than half of high-risk
patients receiving an OAC prescription.
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A trial fibrillation (AF) is the most common cardiacarrhythmia, with an estimated 1 in 4 lifetime risk inthose older than 40 years and a projected increase in
prevalence to approximately 5.6 million affected individuals
by 2050 in the United States.1,2 Atrial fibrillation imparts
stroke risk, and risk stratification schemes that include the
CHADS2 score3 and, more recently, the CHA2DS2-VASc score4
have been developed to estimate the risk of thromboembo-
lism in patients with AF based on specific risk factors.3,4
Consensus guidelines have called for the use of these risk
stratification schemes to determine the absolute risk of
stroke5-7 and aid the health care professional in determining
whether prescription of an oral anticoagulant (OAC) with
warfarin sodium (a vitamin K antagonist) or the newer non–
vitamin K antagonist OACs may be warranted for stroke risk
reduction.8-11 Although it is well known that appropriate
OAC prescription in patients with AF at risk for stroke out-
side of clinical trial settings falls short of guideline-based
expectations,12-15 the extent to which prescription of OACs in
real-world practice increases as the risk of stroke increases is
less well known.
We evaluated the prevalence of OAC prescription by car-
diovascular specialists in a cohort of outpatients using data
from the American College of Cardiology’s National Cardio-
vascular Data Registry (NCDR) Practice Innovation and Clini-
cal Excellence (PINNACLE) Registry. The use of this prospec-
tivenational registryof cardiovascular care in theUnitedStates
provides a unique opportunity to examine patterns of OAC
treatment in routine practice among outpatients. We sought
to examine the prevalence of treatmentwithOACs, antiplate-
let therapyonly, or noantithrombotic therapy inpatientswith
AF across the spectrum of stroke risk as established by the
CHADS2 score and the CHA2DS2-VASc score in real-world US
cardiology practices.
Methods
Data Source
The NCDR PINNACLE Registry was created in 2008 by the
AmericanCollege of Cardiology as the first national, prospec-
tive, office-based cardiac quality improvement registry in the
United States.16,17 Participating academic and private prac-
tices collect longitudinal point-of-care data, including pa-
tient demographics, symptoms, comorbidities, vital signs,
medications, laboratory values, and recent hospitalizations,
with either paper forms or modification of a practice’s elec-
tronic medical record using a standardized collection tool to
comprehensivelyobtainand transmituniformdata.TheNCDR
dataqualityassurance ismaintainedthroughstandardizeddata
collection and transmission protocols, rigorous data defini-
tions,andperiodicdataqualityaudits,whichhaveshownmuch
greater than 90% raw accuracy of data abstraction.18,19 Qual-
ity checks and analyses of the data have been performed at
Saint Luke’sMidAmericaHeart Institute, theprimary analyti-
cal center for the PINNACLE Registry. Waiver of written in-
formed consent and authorization for this studywas granted
by Chesapeake Research Review Incorporated.
Study Population
Therewere2172455patients inthePINNACLERegistrybetween
January1,2008,andDecember30,2012.Weexcluded1714950
patientswithoutadiagnosisofAFand28088patientsdeemed
notable tobeprescribedantiplateletorOACtherapyasassessed
by the treating health care professional and specified on data
collection forms. Therefore, our final study cohort comprised
429417patientswithAF from144practices in 38 states across
theUnitedStates.Wecharacterizedthestudycohortusing2dif-
ferentmetrics toestimate thromboembolic risk inpatientswith
AF.First,weused the traditionalCHADS2score (with 1point for
congestiveheart failure, hypertension, age≥75years, anddia-
betes mellitus and 2 points for stroke or transient ischemic
attack3). Second,weusedtheCHA2DS2-VAScscore (with 1point
forcongestiveheartfailure,hypertension,age≥65years[2points
if age ≥75 years], diabetes mellitus, female sex, and coronary
orperipheral arterialdiseaseand2points for strokeor transient
ischemic attack), amore sensitive tool to risk-stratify patients
withAFwhomaybe at risk for stroke andbenefit fromantico-
agulant therapy.4Theuseof theCHA2DS2-VAScscoremayhave
influencedcardiovascularspecialistprescriptionofanOACdur-
ing thestudy timeframeas reflected inupdated2012European
SocietyofCardiologyguidelines7 and subsequentlypublished
updatedguidelinesafter thestudy.6Theseupdatedguidelines,
publishedafter the study time frame in2014, advise theuseof
theCHA2DS2-VASc score for the assessment of stroke risk.6 To
minimize overrepresentationbypatientswithmultiple visits,
onlydata from the indexvisit of eachpatient during the study
periodwere used. The index visitwas considered the first en-
counteratwhichadiagnosisofAFwasspecified.Toensure that
misclassificationofOACprescriptionwasnotoverlookedbyex-
aminingonly the indexvisit,weperformeda sensitivity analy-
sis to determine the number of patients that would be reclas-
sifiedasbeingprescribedanOACbyincreasingthewindowfrom
baseline towithin 1 year after the indexvisit.Due to ahigh rate
of datamissingness (44.4%), analyses specific to patient race/
ethnicity were not performed.
Study Outcomes
Our primary study outcomewas treatment with any US Food
and Drug Administration–approved OAC for stroke preven-
tion in patients with AF, which included warfarin, dabiga-
tran, or rivaroxaban (apixabanandedoxabanhadnot yet been
approved by the Food and Drug Administration during the
study time frame). Among patients not treated with antico-
agulant therapy,wealsoexaminedwhether thesepatientswere
treated with an antiplatelet agent (including aspirin alone or
aspirin plus a thienopyridine) or were receiving neither OAC
nor antiplatelet therapy.Treatmentwith a thienopyridinewas
defined as prescription of clopidogrel bisulfate, ticlopidine
hydrochloride, or prasugrel.
Statistical Analysis
Normally distributed continuous variables are expressed as
means (SDs), whereas categorical variables are expressed as
proportions. Unadjusted differenceswere compared using χ2
test for categorical variables and 1-way analysis of variance or
t test for continuous variables, as appropriate.
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To investigate the independentassociationsof theCHADS2
scoreandtheCHA2DS2-VAScscoreascontinuousvariableswith
the outcome of antithrombotic therapy prescription, we con-
structed multinomial logistic regression models adjusted for
patient demographic, clinical, and practice characteristics.
These models included site as a random effect to account for
patient clustering within sites. Covariates considered to be
potential confounders were entered in the multivariable
model and included sex, unstable angina, dyslipidemia, prior
coronary arterybypass graft surgery, prior percutaneous coro-
nary intervention,USregion,urban location,clinicvolume,and
health care professional designation. Patient characteristics
that comprised the CHADS2 score or the CHA2DS2-VASc score
were not included in the multivariable model to avoid
collinearity. Covariates selected for the multivariable analy-
ses were chosen based on the plausibility that they could be
associated with differential prescription of anticoagulation.
Statistical testswere 2 sidedandconsidered significant if they
yielded P < .05. Analyses were performed using statistical
software packages, including SAS (version 9.3; SAS Institute
Inc), R (version 2.15.3; R Foundation for Statistical Comput-
ing), and IVEWare (Institute for Social Research,University of
Michigan, Ann Arbor).
Results
Demographic, clinical, and institutional characteristics among
the 429417 patients with AF in the overall cohort, stratified
by prescription of an OAC, are summarized in Table 1. Some
absolutedifferences inbaseline characteristicswere small but
statistically significant between those prescribed anOAC and
those not prescribed an OAC. Patients with AF prescribed an
OAC were older, more often male, and more often resided in
the Northeast andMidwest. Patients prescribed an OACwere
more likely to have a history of hypertension, dyslipidemia,
congestiveheart failure,diabetesmellitus, prior strokeor tran-
sient ischemic attack, prior systemic embolism, and prior
Table 1. Baseline Characteristics of PatientsWith AF Across the Spectrum of Stroke Risk,
Stratified by Prescription of an Oral Anticoagulant
Characteristic
Total Cohort
(N = 429 417)
Prescribed Oral Anticoagulant
P Value
Standardized
Difference
Yes
(n = 192 600)
No
(n = 236 817)
Patient Demographic Characteristics
Age, mean (SD), y 71.3 (12.9) 73.2 (11.0) 69.7 (14.0) <.001 6.67
Male sex, % 55.8 57.5 54.5 <.001 6.02
CHADS2 score, mean (SD) 2.0 (1.3) 2.1 (1.2) 1.9 (1.3) <.001 20.04
CHA2DS2-VASc score, mean (SD) 3.7 (1.8) 3.8 (1.7) 3.5 (1.8) <.001 18.51
Comorbidities, %
Hypertension 76.8 80.4 74.0 <.001 6.67
Coronary artery disease 49.7 48.6 50.5 <.001 3.79
Unstable angina 1.0 0.8 1.2 <.001 4.43
Stable angina 6.4 4.8 7.7 <.001 12.01
Dyslipidemia 55.2 57.5 53.4 <.001 8.39
Congestive heart failure 24.9 28.4 22.1 <.001 14.50
Prior stroke or
transient ischemic attack
14.3 14.8 13.8 <.001 2.81
Prior systemic embolism 1.2 1.4 1.0 <.001 3.91
Peripheral arterial disease 8.5 7.7 9.0 <.001 4.65
Diabetes mellitus 22.9 23.7 22.2 <.001 3.67
Prior myocardial infarction 17.9 18.1 17.7 <.001 1.04
Prior CABG surgery 8.7 8.5 9.0 <.001 1.69
Institutional Characteristics
US region, %
Northeast 13.5 14.6 12.6
<.001
8.47
Midwest 28.2 34.1 23.3 24.05
South 38.7 33.5 43.0 19.57
West 19.6 17.8 21.1 5.87
Urban location, % 86.7 89.1 84.7 <.001 12.98
Clinic volume, mean (SD)
visits per year
36 276.5
(27 661.9)
36 915.4
(27 261.5)
35 756.9
(27 972.6)
<.001 4.19
Health care professional
designation, %
Physician 94.2 94.3 94.2
<.001
1.11
Nurse practitioner 4.1 4.4 3.9 2.82
Other 1.6 1.2 1.9 1.20 Abbreviations: AF, atrial fibrillation;
CABG, coronary artery bypass graft.
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myocardial infarction. Patients prescribed an OAC were less
likely to have coronary artery disease, unstable angina, stable
angina, peripheral arterial disease, and prior coronary artery
bypass graft surgery.
The cohort’s mean (SD) CHADS2 score and CHA2DS2-
VASc score were 2.0 (1.3) and 3.7 (1.8), respectively (Table 1).
The full distribution of patient CHADS2 scores and CHA2DS2-
VASc scores is shown in Figure 1.
A total of 192 600 patients (44.9%) with AF were pre-
scribedanOAC.Warfarinwas themostcommonlyusedtherapy
(173832 [90.3%]), followed by dabigatran (14896 [7.7%]) and
rivaroxaban (3872 [2.0%]). Of the total cohort, 111 134 patients
(25.9%) were prescribed aspirin only, 23454 patients (5.5%)
were prescribed aspirin plus thienopyridine dual antiplatelet
therapy, and 102229 patients (23.8%) were prescribed no an-
tithrombotic therapy.TheprevalenceofprescriptionofanOAC
(stratified by warfarin vs dabigatran or rivaroxaban), aspirin
only, aspirin plus a thienopyridine, and no antithrombotic
therapy across the spectrum of the CHADS2 score and the
CHA2DS2-VAScscore is showninFigure2. PatientswithAFwith
Figure 2. Prevalence of Antithrombotic Therapies in PatientsWith Atrial Fibrillation (AF) Across the Spectrum of Stroke Risk by the CHADS2 Score
and the CHA2DS2-VASc Score
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Shown is the proportion of patients treated with different antithrombotic
therapies based on the CHADS2 score (A) and the CHA2DS2-VASc score (B).
Oral anticoagulant therapy was defined as prescription of either warfarin
sodium, dabigatran, or rivaroxaban, further stratified by warfarin (dark blue) vs
dabigatran or rivaroxaban (dark brown). Other treatment strategies included
prescription of aspirin only (light brown), aspirin plus a thienopyridine (light
blue), or no antithrombotic therapy (light grey). Treatment with a
thienopyridine was defined as prescription of clopidogrel bisulfate, ticlopidine
hydrochloride, or prasugrel.
Figure 1. Prevalence of PatientsWith Atrial Fibrillation (AF) Across the Spectrum of the CHADS2 Score and the CHA2DS2-VASc Score
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Distribution of CHA2DS2-VASc scores within the cohortB
Shown is the distribution of patients with AF in the cohort characterized by the CHADS2 score (A) and the CHA2DS2-VASc score (B).
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a CHADS2 score of 3 and a CHA2DS2-VASc score of 5weremost
often prescribed anticoagulation at 50.6% and 49.7%, respec-
tively.Oral anticoagulantprescriptiondidnotexceed50%even
in higher-risk patients, including patients with AF with a
CHADS2 score exceeding 3 or a CHA2DS2-VASc score exceed-
ing 4. The prevalence of non–vitaminK antagonist OAC (dabi-
gatranandrivaroxaban)prescriptiondidnotexceed4.5%across
the CHADS2 score and the CHA2DS2-VASc score. In a sensitiv-
ityanalysis evaluating reclassificationofpatientsprescribedan
OAC within 1 year of the index visit, a small proportion of pa-
tients (4859 [2.1%]) not prescribed an anticoagulant at base-
linewereprescribedanOACinfollow-up.Evaluationofpractice-
level variation of OAC prescription revealed that the median
practice rate for OAC prescription was 51.7%. There was sig-
nificant variation in OAC prescription, with an interquartile
range of 37.7% to 58.3% (Figure 3).
In both unadjusted and multivariable-adjusted analyses,
each 1-point increase in the CHADS2 score and the CHA2DS2-
VAScscorewassignificantlyassociatedwithgreateroddsofboth
antiplatelet therapyandOACprescription (Table2).Notably, for
each1-point increase in theCHADS2score,patientswithAFhad
a 16.6%greater odds of OACprescription vs no antithrombotic
therapy prescription (adjusted odds ratio [OR], 1.166; 95% CI,
1.152-1.180;P < .001) anda 15.8%greateroddsofOACprescrip-
tion vs aspirin-only prescription (adjusted OR, 1.158; 95% CI,
1.144-1.172;P < .001). Similarly, for each 1-point increase in the
CHA2DS2-VAScscore, thesamepatientshada19.0%greaterodds
ofOACprescriptionvsnoantithrombotic therapy (adjustedOR,
1.190; 95% CI, 1.184-1.196; P < .001) and a 16.3% greater odds
of OACprescription vs aspirin-only prescription (adjustedOR,
1.163; 95% CI, 1.157-1.169; P < .001). The association of all co-
variates included in the adjusted multivariable models evalu-
ating the CHADS2 score and the CHA2DS2-VASc score and the
oddsofantithrombotic therapyprescriptionaresummarized in
the eTable in the Supplement.
Discussion
In a large quality improvement registry of 429 417 outpa-
tientswith AF across the spectrumof stroke risk asmeasured
by theCHADS2scoreandtheCHA2DS2-VAScscore, each1-point
increase in either score was associated with an approxi-
mately 15% greater adjusted odds of OAC prescription. Over-
all, there appeared to be a plateau effect of OAC prescription
across the spectrum of stroke risk because patients with a
CHADS2 score exceeding 3 or a CHA2DS2-VASc score exceed-
ing 4were often not prescribed an OAC evenwhen compared
with their lower-risk counterparts, and OAC prescription did
not exceed 50% in these highest-risk patients. Our findings
have important implications for patients with AF, particu-
larly because annual stroke risk increaseswith the number of
stroke risk factors measured by the CHADS2 score and the
CHA2DS2-VASc score.3,4 Therefore, the lack of guideline-
adhering prescription of OACs for stroke prophylaxis in pa-
tients with the highest CHADS2 scores and CHA2DS2-VASc
scoresshoulddrawattention toa treatmentgap inpatientswho
maymost appropriately need OAC therapy.
Despite a well-established association of AF with stroke,
significant lack of OAC prescription to reduce thromboembo-
lism in at-risk candidates has been demonstrated in several
large-scale studies.13,20,21Thesepreviousstudiesdescribedpri-
marilyUSpatients in theeraofwarfarin therapyandbefore the
promulgation of the importance of stroke risk scores to aid in
risk stratification. Clinical risk scores that include theCHADS2
scoreand theCHA2DS2-VAScscorehavebeendeveloped toelu-
cidate andquantify stroke risk inpatientswithAF to aid in the
decision toprescribeantithrombotic therapies.3,4 Inour study,
we used the CHADS2 score because this risk scheme was the
predominant scoring system contemporary with the study
period.22 Toexpandon the robustness of our findings,wealso
studied the samecohort of patientswithAFas assessedby the
CHA2DS2-VAScscorebecausethis riskschememayimprovedis-
crimination of patients with AF at risk for stroke and throm-
boembolism and is supported by updated guidelines pub-
lishednear theendofandafter the timeframeof thestudy.6,7,23
In theGARFIELD (GlobalAnticoagulantRegistry in theFIELD)
multinational observational study24of 10614patientswithAF
enrolled between 2009 and 2011 at 540 sites in 19 non-US
countries and cared for by general practitioners, cardiolo-
gists, andneurologists, 38.0%ofpatientswith aCHADS2 score
of 2 or higher did not receive anticoagulant therapy. A similar
plateaueffectasseeninourstudywasobservedathigherranges
of CHADS2 scores and CHA2DS2-VASc scores in the GARFIELD
registry.Ourcohortwascompletely composedofpatients from
theUnitedStates treatedbycardiovascular specialists.The lack
ofprescriptionof anOACbycardiovascular specialists inmore
than 50% of patients at the highest thromboembolic risk cat-
egories suggests thatUScardiovascularhealth careprofession-
als, who should be well versed in guideline-based therapy for
AF, may not fully appreciate the continued increased risk of
thromboembolismwithaccumulationof additional stroke risk
factors. This deficit has been highlighted in the lack of corre-
lation between empirical risk scores and physician assess-
ment of stroke risk in 10094patientswithAF in theORBIT-AF
Figure 3. Variation in Oral Anticoagulant (OAC) Prescription Prevalence
Across Practices
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Themedian practice treatment prevalence with OAC therapy was 51.7%, with
an interquartile range of 37.7% to 58.3%. Each practice is given a number
representing the proportion of patients with atrial fibrillation within that
practice prescribed an OAC.
Oral Anticoagulant Therapy in Patients With Atrial Fibrillation Original Investigation Research
jamacardiology.com (Reprinted) JAMA Cardiology April 2016 Volume 1, Number 1 59
Downloaded From: https://jamanetwork.com/ by a University Of North Carolina - Chapel Hill User  on 08/14/2019
Copyright 2016 American Medical Association. All rights reserved.
(Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation).25 Other explanations need to be entertained for
the lackofOACprescription inhigh-riskpatients, including jus-
tifiable clinical reasons or patient refusal of this therapy. Dif-
ferences inOACprescriptionprevalencebetweentheORBIT-AF
and the PINNACLE Registry may not be directly comparable.
In general, the PINNACLE Registry cohort was composed of a
much larger population of patients with AF treated specifi-
cally by cardiovascular disease specialists,whereas the indus-
try-sponsored ORBIT-AF was a smaller cohort and also in-
cluded patients with AF treated by internists. We observed a
lower prevalence of OAC prescription in the South compared
with the Midwest and Northeast. The reason for such varia-
tion intreatmentpatternsamongdifferent regions in theUnited
States is unclear but may be related to differences in insur-
ancecoverage, socioeconomicstatus,orexposureofhealthcare
professionals in different regions to guidelines through
educational programs.
The reasons underlying the associations observed, par-
ticularly the plateau effect at higher risk scores, remain un-
known.Becausemanyof the risk factors incorporated into the
CHADS2 score and theCHA2DS2-VASc score that predict stroke
risk in patients with AF are the same risk factors that predict
bleeding complications in patients prescribed anOAC (eg, the
HAS-BLEDscore26), health careprofessionalsmaybemore re-
luctant toprescribeanticoagulation in thesesickerpatientsdue
to concerns regarding bleeding risk. Most important, despite
theheightenedbleeding riskwithhigherHAS-BLEDscores, the
benefit of anticoagulation continues tooutweigh the risk as all
of these scores increase.27 In addition, risk factors for stroke,
such as age, diabetes mellitus, hypertension, prior stroke or
transient ischemic attack, or coronary artery disease and its
equivalents (eg, angina and previous revascularization), may
necessitate treatmentwith aspirinor evenaspirinplus thieno-
pyridine dual antiplatelet therapy. Given increased risk of
bleedingwith the additionof anOAC to antiplatelet therapy28
or the incorrectperceptionthatantiplatelet therapy(evenwhen
aspirin is combinedwith clopidogrel) has a similar efficacy as
anticoagulation,29,30 health care professionalsmay avoid ad-
ditional antithrombotic therapy in patients taking antiplate-
let therapy. However, because more than 50% of high-risk
patients had anticoagulation withheld in the absence of anti-
platelet therapy, these considerations cannot fully explainour
results. Althoughwe focusedon relationships betweenestab-
lishedstrokeriskscoresandanticoagulationprescriptionacross
the entire PINNACLE Registry, there was significant variabil-
ity among individual practices (Figure 3). This finding sug-
gests that focusing on factors pertinent to practices that are
the least and most compliant with related guideline adher-
ence may prove fruitful in efforts to rectify inadequate anti-
coagulation prescription more broadly.
Because dabigatran and rivaroxaban were approved
toward the end of our study time frame, most patients pre-
scribed an OAC in our cohort were prescribed warfarin. Our
study time frame concluded in 2012, and it is possible that
practice patterns may have changed since that time given
the subsequent growing availability of several approved
OACs. Although 4 non–vitamin K antagonist OACs are now
available in clinical practice, warfarin remains the most com-
mon drug prescription for anticoagulation in AF,31 making
these data relevant to contemporary practice.
Our study has some limitations. First, while the
PINNACLE Registry ascertains whether an anticoagulant is
contraindicated, the data are not sufficiently granular to cal-
culate the HAS-BLED score (ie, the PINNACLE Registry does
not capture data on medication use predisposing to bleeding,
labile international normalized ratios, or alcohol or drug
use).26 This additional information may have been helpful to
quantify the bleeding risk among those who did and did not
receive an anticoagulation prescription. Second, the
Table 2. Association of the CHADS2 Score and the CHA2DS2-VASc ScoreWith Prescription of Antithrombotic Therapy
Antithrombotic
Therapy Prescription
CHADS2 Score CHA2DS2-VASc Score
Unadjusted Analysis Adjusted Analysisa Unadjusted Analysis Adjusted Analysisb
OR (95% CI)c P Value
Adjusted OR
(95% CI)c P Value OR (95% CI)c P Value
Adjusted OR
(95% CI)c P Value
No antithrombotic
therapy
1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Oral anticoagulant 1.248
(1.240-1.256)
<.001 1.166
(1.152-1.180)
<.001 1.174
(1.168-1.179)
<.001 1.190
(1.184-1.196)
<.001
Aspirin plus a
thienopyridine
1.350
(1.335-1.365)
<.001 1.189
(1.181-1.196)
<.001 1.354
(1.343-1.365)
<.001 1.274
(1.262-1.286)
<.001
Aspirin only 1.065
(1.057-1.072)
<.001 1.011
(1.003-1.018)
.01 1.049
(1.044-1.055)
<.001 1.031
(1.025-1.036)
<.001
Aspirin only 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Oral anticoagulant 1.172
(1.165-1.179)
<.001 1.158
(1.144-1.172)
<.001 1.119
(1.114-1.23)
<.001 1.163
(1.157-1.169)
<.001
Aspirin plus a
thienopyridine
1.267
(1.254-1.281)
<.001 1.185
(1.178-1.193)
<.001 1.290
(1.280-1.301)
<.001 1.254
(1.242-1.267)
<.001
Abbreviations: CABG, coronary artery bypass graft; NA, not applicable;
OR, odds ratio.
a Adjusted for sex, unstable angina, dyslipidemia, prior CABG surgery, prior
percutaneous coronary intervention, US region, urban location, clinic volume,
and health care professional designation.
bAdjusted for unstable angina, dyslipidemia, prior CABG surgery, prior
percutaneous coronary intervention, US region, urban location, clinic volume,
and health care professional designation.
c The OR represents the odds of antithrombotic therapy prescription compared
with the reference group (either no antithrombotic therapy or aspirin only) per
1-point score increase in the continuous predictor variable (CHADS2 score and
CHA2DS2-VASc score).
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PINNACLE program enrolled patients from 144 academic and
private cardiology practices in 38 states across the United
States, which are potentially more dedicated to quality
improvement. Therefore, antithrombotic therapy prescrip-
tion patterns in other US or international practices or by non-
cardiology health care professionals may differ from those
reported in this study, potentially reducing the generalizabil-
ity of our results. Third, specific data are unavailable regard-
ing previous bleeding complications or exact reasons for con-
traindications to anticoagulant therapy; therefore, we cannot
determine the validity of a reported contraindication.
Although the lack of this and other outcome data, such as
stroke and major bleeding events, are shortcomings of the
PINNACLE Registry, the large number of patients included in
our analyses provides substantial power in evaluating the pri-
mary focus of our analyses, which is prescription of an OAC
in patients with AF across the spectrum of stroke risk.
Fourth, themain data analyzed consisted of OAC prescription
at the index AF visit. Although the index visit may not cap-
ture OAC prescription at any time in patient follow-up, a sen-
sitivity analysis that included follow-up visits until 1 year
after the index visit demonstrated that only a small propor-
tion of additional patients (approximately 2%) were pre-
scribed an OAC. Fifth, some may argue that the PINNACLE
data collection formmay not reflect actual prescription of the
drug and much less what patients actually receive or con-
sume. However, that distinction is arguably minimally rel-
evant for the purposes of this study because it is likely that
the data recorded on the form more purely mirror the intent
or perceived “correct” prescription of medications. Neverthe-
less, we cannot rule out the possibility that, despite best
efforts for accurate data collection, underreporting of OAC
prescription occurred by those recording this information.
Conclusions
Data fromthisquality improvement registryof cardiologyout-
patientswithAFacross thespectrumof stroke risk suggest that
cardiovascular disease specialists were more likely to pre-
scribe an OAC as the number of stroke risk factors increased
basedonboth theCHADS2 score and theCHA2DS2-VASc score.
However, less than 50% of all patients at the highest ranges
of stroke riskwereprescribed anOAC.These findingsdrawat-
tention to important gaps in appropriate treatment of pa-
tients with AF at the highest risk of stroke and highlight op-
portunities to understand the reasons behind these gaps and
insights to improve them.
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